MX2021012047A - Polipeptidos de fusion de serpina y metodos para utilizar los mismos. - Google Patents

Polipeptidos de fusion de serpina y metodos para utilizar los mismos.

Info

Publication number
MX2021012047A
MX2021012047A MX2021012047A MX2021012047A MX2021012047A MX 2021012047 A MX2021012047 A MX 2021012047A MX 2021012047 A MX2021012047 A MX 2021012047A MX 2021012047 A MX2021012047 A MX 2021012047A MX 2021012047 A MX2021012047 A MX 2021012047A
Authority
MX
Mexico
Prior art keywords
polypeptide
derived
methods
molecules
amino acid
Prior art date
Application number
MX2021012047A
Other languages
English (en)
Inventor
Quinn Deveraux
Brendan P Eckelman
John C Timmer
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/524,832 external-priority patent/US10400029B2/en
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2021012047A publication Critical patent/MX2021012047A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

Esta invención está relacionada a moléculas, particularmente polipéptidos, más particularmente proteínas de fusión que incluyen un polipéptido de serpina o una secuencia de aminoácidos que se deriva de una serpina y un segundo polipéptido que comprende al menos uno de los siguientes: un polipéptido Fc o una secuencia de aminoácidos que se deriva de un polipéptido Fc; un polipéptido dirigido a citoquinas o una secuencia derivada de un polipéptido dirigdo a citoquinas; un polipéptido que contiene un dominio WAP o una secuencia derivada de un polipéptido que contiene un dominio WAP; y un polipéptido de albúmina o una secuencia de aminoácidos que se deriva de un polipéptido de albúmina de suero; esta invención también está relacionada a métodos para utilizar tales moléculas en una variedad de indicaciones terapéuticas y de diagnóstico, así como también métodos para producir tales moléculas.
MX2021012047A 2014-10-27 2017-04-26 Polipeptidos de fusion de serpina y metodos para utilizar los mismos. MX2021012047A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/524,832 US10400029B2 (en) 2011-06-28 2014-10-27 Serpin fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021012047A true MX2021012047A (es) 2021-11-03

Family

ID=55858243

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005467A MX2017005467A (es) 2014-10-27 2015-10-27 Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
MX2021012047A MX2021012047A (es) 2014-10-27 2017-04-26 Polipeptidos de fusion de serpina y metodos para utilizar los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005467A MX2017005467A (es) 2014-10-27 2015-10-27 Polipéptidos de fusión de serpina y métodos para utilizar los mismos.

Country Status (14)

Country Link
EP (1) EP3212290A4 (es)
JP (2) JP6737781B2 (es)
KR (2) KR20240005109A (es)
CN (2) CN107206257A (es)
AU (2) AU2015339507B2 (es)
BR (1) BR112017008525A2 (es)
CA (1) CA2965151A1 (es)
HK (1) HK1244460A1 (es)
IL (2) IL308589A (es)
MX (2) MX2017005467A (es)
RU (1) RU2746550C2 (es)
SG (2) SG11201703390SA (es)
UA (1) UA127305C2 (es)
WO (1) WO2016069574A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286816A (zh) * 2018-10-29 2021-08-20 斯宾疗法有限责任公司 用于α-1-抗胰蛋白酶病症的组合物和方法
WO2020097946A1 (zh) * 2018-11-18 2020-05-22 杭州博虎生物科技有限公司 一种重组人白细胞介素10融合蛋白及其应用
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
US20240067703A1 (en) * 2020-12-21 2024-02-29 Macquarie University Treatment of glaucoma
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
JP2024509543A (ja) * 2021-03-03 2024-03-04 フォーマイコン アーゲー ＡＣＥ２ Ｆｃ融合タンパク質の製剤
CN113325181A (zh) * 2021-04-25 2021-08-31 苏州市立医院(北区) 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用
CN114874333A (zh) * 2021-10-18 2022-08-09 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
US20230364208A1 (en) 2022-05-16 2023-11-16 Inhibrx, Inc. Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161532A1 (en) * 1999-03-01 2001-12-12 Human Genome Sciences, Inc. Human serpin proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
BRPI0412761A (pt) * 2003-07-18 2006-09-26 Vertex Pharma inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
WO2005019434A2 (en) * 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
WO2007014123A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2618951A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
AU2009262199B2 (en) * 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
KR20110104032A (ko) * 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
HUE033205T2 (en) * 2010-12-23 2017-11-28 Janssen Biotech Inc Active, protease-resistant antibody-FC mutant
WO2012130831A1 (en) * 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
ES2746052T3 (es) * 2011-06-28 2020-03-04 Inhibrx Lp Polipéptidos de fusión de serpina y métodos de uso de los mismos
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
EP2802653A4 (en) * 2012-01-10 2015-09-02 Univ Colorado Regents ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF
MX2014015557A (es) * 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
RU2015100656A (ru) * 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
BR112015002263A2 (pt) * 2012-08-02 2017-12-12 Hoffmann La Roche polipeptídeo de fusão, polipeptídeo de fusão dimérico, método para a produção de um receptor fc solúvel, uso de um polipeptídeo de fusão imobilizado e composição farmacêutica
EP2929045B1 (en) * 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides

Also Published As

Publication number Publication date
IL251799B1 (en) 2023-12-01
BR112017008525A2 (pt) 2018-01-30
HK1244460A1 (zh) 2018-08-10
SG10201903142RA (en) 2019-05-30
UA127305C2 (uk) 2023-07-19
JP2020180157A (ja) 2020-11-05
AU2015339507B2 (en) 2021-07-01
CN107206257A (zh) 2017-09-26
AU2021240153A1 (en) 2021-10-28
CA2965151A1 (en) 2016-05-06
EP3212290A1 (en) 2017-09-06
AU2015339507A1 (en) 2017-05-11
IL251799B2 (en) 2024-04-01
KR20170091096A (ko) 2017-08-08
RU2017118325A (ru) 2018-11-29
RU2017118325A3 (es) 2019-03-21
JP6737781B2 (ja) 2020-08-12
RU2746550C2 (ru) 2021-04-15
MX2017005467A (es) 2017-11-30
JP2017537888A (ja) 2017-12-21
KR20240005109A (ko) 2024-01-11
WO2016069574A1 (en) 2016-05-06
EP3212290A4 (en) 2019-01-23
CN114316068A (zh) 2022-04-12
IL308589A (en) 2024-01-01
IL251799A0 (en) 2017-06-29
SG11201703390SA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX356517B (es) Polipéptidos de fusión de serpina y métodos de uso de los mismos.
MX2013015324A (es) Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
PH12019500596A1 (en) Recombinant binding proteins and their use
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
WO2016065323A3 (en) Single domain antibodies directed against intracellular antigens
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
NZ724196A (en) Uti fusion proteins
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови